Combination treatment before and after stomach cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of experimental drugs (IBI343, Sintilimab, and chemotherapy) before and after surgery for a specific type of stomach cancer that is CLDN18.2 positive. The goal is to see if this treatment shrinks the tumor and helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of stomach cancer that is positive for the CLDN18.2 protein.
- You should be between 18 and 75 years old and in fairly good health (able to do daily activities).
- Your cancer must be at a stage where it has spread to nearby lymph nodes but not to distant organs, and you are able to have surgery to remove it.
- You cannot have had chemotherapy or other cancer treatments for this stomach cancer before joining the trial.
- You must have good organ function (heart, liver, kidneys, bone marrow) as shown by blood tests and an echocardiogram.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests whether adding an immunotherapy drug called sintilimab to chemotherapy and radiation before surgery can help shrink tumors and improve outcomes for people with gastroesophageal junction cancer. It is designed for patients who have not had previous treatment for this cancer.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from coming back. You may qualify if you had D2 surgery and your tumor tested positive for PD-L1.
This trial tests a combination of chemotherapy drugs and an immunotherapy drug given before surgery for stomach cancer in younger patients. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of four drugs given before surgery to shrink stomach cancer and improve the chances of successful removal. It is for people with locally advanced stomach or gastroesophageal junction cancer that has not been treated yet.
This trial tests a new approach for stomach cancer that hasn't spread. You'd get a combination of an investigational drug targeting a specific protein on cancer cells, an immunotherapy that helps your immune system fight cancer, and standard chemotherapy before surgery. The goal is to see if this makes the tumor shrink more and improves outcomes.
Hear when a new Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.